Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Determination of the toxicity of standard dose cetuximab together with concurrent individualised, isotoxic accelerated radiotherapy and cisplatin-vinorelbine for patients with stage III non-small cell lung cancer: A phase I study.

Trial Profile

Determination of the toxicity of standard dose cetuximab together with concurrent individualised, isotoxic accelerated radiotherapy and cisplatin-vinorelbine for patients with stage III non-small cell lung cancer: A phase I study.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2014

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Jul 2011 Actual end date (1 Jul 2011) added as reported by ClinicalTrials.gov record.
    • 18 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 21 Jun 2011 Planned End Date changed from 1 Jan 2010 to 1 May 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top